Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2004

View Archived Issues

Phase I studies evaluate the effects of SPD-754 on the metabolism of other anti-HIV drugs

Novel class of HIV-1 entry inhibitors targets gp120-binding domain of CD4

A recombinant vaccine shows promise in the prevention of SARS

Signet outlines plans for efforts in sepsis and acute renal failure

Celera Genomics and Seattle Genetics to develop antibody therapies for cancer

Several drugs show efficacy in the treatment of HIV-associated lipodystrophy

Hypocholesterolemic compound reduces Abeta levels in vivo

PBI-1393 activates CTLs and induces IL-2 and IFN-gamma synthesis

Flurbiprofen analogues reduce beta-amyloid release without affecting COX-1 activity

FDA to grant additional six months pediatric exclusivity to clofarabine

AzaSite enters two phase III studies for acute bacterial conjunctivitis

ViroPharma to advance maribavir into phase II

Atrix licenses BEMA technology to Arius

Pfizer to discontinue development of sumanirole

Access updates progress of AP-5346

DMAG enters phase I

Evotec to support Morphochem's development of Oxaquin

NEC discovers new peptide-vaccine candidates for hepatitis C

LY-450139 reported to reduce the levels of amyloid beta in plasma and CSF

Farnesoid X receptor agonists

New JNK3 inhibitors with potential utility in cerebral ischemia

Selective 5-HT6 antagonists claimed by Roche

Prodrugs of MPV-2426 described by Orion

Boehringer Ingelheim discloses anti-HIV agents

Glucokinase activators described by Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...